All In Biotech

NDA 209445 · Shionogi

Fetroja

Cefiderocol Sulfate Tosylate · Intravenous

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 14, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

19

3 Phase 3, 3 recruiting

FAERS reports

315

282 serious, 147 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 24, 2026.

FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Complicated Urinary Tract Infections (cUTIs), Including Pyelonephritis FETROJA ® is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , and Enterobacter cloacae complex [see Clinical Studies (14.1) ] . 1.2 Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) FETROJA is indicated in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible Gram-negative microorganisms: Acinetobacter baumannii complex, Escherichia coli , Enterobacter cloacae complex, Klebsiella pneumoniae , Pseudomonas aeruginosa , and Serratia marcescens [see Clinical Studies (14.2) ]. 1.3 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven...

Mechanism: FETROJA is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 25, 2020 Supplement 2 · Efficacy · priority review LabelLetterReview
  • Nov 14, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • FETROJA · CEFIDEROCOL SULFATE TOSYLATE EQ 1GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefiderocol" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death71
  • drug resistance31
  • treatment failure27
  • off label use26
  • acute kidney injury23
  • pathogen resistance17
  • hepatic cytolysis14
  • multiple organ dysfunction syndrome14
  • infection13
  • cholestasis12
  • condition aggravated11
  • septic shock11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202011
202132
202271
202382
202468
202533
202618

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fetroja (Cefiderocol Sulfate Tosylate)

2024 spending

$6.9M

Beneficiaries

345

1,794 claims

Per beneficiary

$20,073

$24.32 per unit

View as table
YearSpending
2020$145,378
2021$1,965,494
2022$2,150,962
2023$4,298,680
2024$6,925,287

Part B: Fetroja (Cefiderocol Sulfate Tosylate) · HCPCS J0699

2024 spending

$43K

Beneficiaries

24

27 claims

Per beneficiary

$1,812

2024 ASP limit $2.22 per unit

View as table
YearSpending
2020$0
2021$30,639
2022$182,277
2023$76,802
2024$43,498

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Shionogi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.